4.6 Article

Plasminogen activator inhibitor-1 reduces cardiac fibrosis and promotes M2 macrophage polarization in inflammatory cardiomyopathy

Journal

BASIC RESEARCH IN CARDIOLOGY
Volume 116, Issue 1, Pages -

Publisher

SPRINGER HEIDELBERG
DOI: 10.1007/s00395-020-00840-w

Keywords

Alpha-smooth muscle actin; DCM; DCMi; Inflammatory cardiomyopathy; Myocarditis; Cardiac fibrosis; Myofibroblast; Macrophages; Monocytes; PAI-1; TGF-beta

Funding

  1. ERA-Net on Cardiovascular Diseases (ERA-CVD
  2. Berlin, Germany) [JTC2016-40-158]
  3. ERA-Net on Cardiovascular Diseases (ERA-CVD
  4. Rome, Italy) [JTC2016-40-158]
  5. ERA-Net on Cardiovascular Diseases (ERA-CVD
  6. Madrid, Spain) [JTC2016-40-158]
  7. German Research Foundation (DFG), Transregional Collaborative Research Center Inflammatory Cardiomyopathy-Molecular Pathogenesis and Therapy

Ask authors/readers for more resources

The study showed that elevated levels of PAI-1 in high-grade DCMi patients are associated with reduced cardiac fibrosis, decreased TGF-beta levels, and fewer myofibroblasts. Additionally, high-grade DCMi patients exhibited a higher proportion of M2 macrophages compared to M1 macrophages, suggesting a role of PAI-1 in macrophage polarization in inflammatory cardiomyopathies.
Plasminogen activator inhibitor-1 (PAI-1) has a cardioprotective function in mice by repressing cardiac fibrosis through TGF-beta and plasminogen-mediated pathways. In addition it is known to be involved in the recruitment and polarization of monocytes/macrophages towards a M2 phenotype in cancer. Here, we investigated the expression of PAI-1 in human dilated cardiomyopathy (DCM) and inflammatory dilated cardiomyopathy (DCMi) and its effect on cardiac fibrosis and macrophage polarization. We retrospectively analyzed endomyocardial biopsies (EMBs) of patients with DCM or DCMi for PAI-1 expression by immunohistochemistry. Furthermore, EMBs were evaluated for the content of fibrotic tissue, number of activated myofibroblasts, TGF-beta expression, as well as for M1 and M2 macrophages. Patients with high-grade DCMi (DCMi-high, CD3(+) lymphocytes > 30 cells/mm(2)) had significantly increased PAI-1 levels compared to DCM and low-grade DCMi patients (DCMi-low, CD3(+) lymphocytes = 14-30 cells/mm(2)) (15.5 +/- 0.4% vs. 1.0 +/- 0.1% and 4.0 +/- 0.1%, p <= 0.001). Elevated PAI-1 expression in DCMi-high subjects was associated with a diminished degree of cardiac fibrosis, decreased levels of TGF-beta and reduced number of myofibroblasts. In addition, DCMi-high patients revealed an increased proportion of non-classical M2 macrophages towards classical M1 macrophages, indicating M2 macrophage-favoring properties of PAI-1 in inflammatory cardiomyopathies. Our findings give evidence that elevated expression of cardiac PAI-1 in subjects with high-grade DCMi suppresses fibrosis by inhibiting TGF-beta and myofibroblast activation. Moreover, our data indicate that PAI-1 is involved in the polarization of M2 macrophages in the heart. Thus, PAI-1 could serve as a potential prognostic biomarker and as a possible therapeutic target in inflammatory cardiomyopathies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available